|
May 10
|
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
|
|
May 10
|
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
|
|
May 8
|
Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
|
|
May 7
|
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
|
|
May 6
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
|
|
May 6
|
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
|